Drug Shortage Report for MAGNESIUM SULFATE INJECTION, USP

Last updated on 2021-01-26 History
Report ID 127839
Drug Identification Number 02139499
Brand name MAGNESIUM SULFATE INJECTION
Common or Proper name Magnesium Sulfate Injection
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) MAGNESIUM SULFATE
Strength(s) 500MG
Dosage form(s) SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS
Packaging size 500 mg/mL, SD Vial, 50 mL
ATC code B05XA
ATC description I.V. SOLUTION ADDITIVES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-11-04
Estimated end date Unknown
Actual end date 2020-12-22
Shortage status Resolved
Updated date 2021-01-26
Company comments Fresenius Kabi Canada Ltd. regrets to advise that due to increased demand and production delays, we will be placing this product on 50% allocation effective today, Wednesday, November 4, 2020. AND C96410P to cover 50 % of the 50 mL demand on a 5:1 ratio) UPDATE Fresenius Kabi Canada Ltd. is pleased to advise that we will be increasing the allocation placed on our Magnesium Sulfate Injection 500 mg/mL SD Vial 50 mL to 100% effective December 22, 2020. Please note that Magnesium Sulfate Injection 500 mg/mL SD Vial 10 mL remains on 100% allocation.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v4 2021-01-26 French Compare
v3 2021-01-26 English Compare
v2 2020-11-05 French Compare
v1 2020-11-05 English Compare

Showing 1 to 4 of 4